Efficacy of Long Term Plavix Therapy Post Angioplasty

• Status: Completed
• Trial end date: 2014-10-01
• Target enrollment: 0
• Participant gender: All

Summary

1010 patients post stenting were enrolled to receive Plavix more than 12 months and less than that and rate of bleeding, complication and major cardiovascular adverse events ( MACE) were compared to evaluate safety and feasibility of long term Plavix therapy post stenting.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shiraz University of Medical Sciences
• Collaborators: Baghiatallah University of Medical Sciences; Baqiyatallah university of medical sciences
• Treatments: Clopidogrel; Ticlopidine

Criteria

Inclusion Criteria:

• post stent ( lesion more than 70% and vessel more than 2.25 mm )

Exclusion Criteria:

• allergy to acetylsalicylic acid or clopidogrel,

• planned surgery within 24 months of percutaneous coronary intervention unless the dual antiplatelet therapy could be maintained throughout the perisurgical period

• history of bleeding diathesis

• major surgery within 15 days

• active bleeding

• previous stroke in the past 6 months

• concomitant or foreseeable need for oral anticoagulation therapy

• pregnancy, life expectancy <24 months, participation in another trial

• inability to provide informed consent